糖尿病性末梢神経障害治療薬の世界市場:パイプラインレビュー(2019上半期)

【英語タイトル】Diabetic Peripheral Neuropathy - Pipeline Review, H1 2019

Global Markets Directが出版した調査資料(DATA906A140)・商品コード:DATA906A140
・発行会社(調査会社):Global Markets Direct
・発行日:2019年4月29日
・ページ数:80
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprisewide(複数事業所内共有可)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Diabetic Peripheral Neuropathy – Pipeline Review, H1 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Peripheral Neuropathy – Pipeline Review, H1 2019, provides an overview of the Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline landscape.

“Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legsand feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain ordiscomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tonein the feet and lower legs, loss of balance, dry feet and cracked skin. The predisposing factors include diabetes,smoking and kidney diseases. Treatment includes antidepressants, anti-seizure and opioid analgesics.”

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Diabetic Peripheral Neuropathy – Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 7, 3 and 9 respectively.

Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Diabetic Peripheral Neuropathy – Overview
Diabetic Peripheral Neuropathy – Therapeutics Development
Diabetic Peripheral Neuropathy – Therapeutics Assessment
Diabetic Peripheral Neuropathy – Companies Involved in Therapeutics Development
Diabetic Peripheral Neuropathy – Drug Profiles
Diabetic Peripheral Neuropathy – Dormant Projects
Diabetic Peripheral Neuropathy – Discontinued Products
Diabetic Peripheral Neuropathy – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Diabetic Peripheral Neuropathy, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Diabetic Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H1 2019
Diabetic Peripheral Neuropathy - Pipeline by Applied Therapeutics Inc, H1 2019
Diabetic Peripheral Neuropathy - Pipeline by Celularity Inc, H1 2019
Diabetic Peripheral Neuropathy - Pipeline by Commence Bio Inc, H1 2019
Diabetic Peripheral Neuropathy - Pipeline by Grunenthal GmbH, H1 2019
Diabetic Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H1 2019
Diabetic Peripheral Neuropathy - Pipeline by Medifron DBT Co Ltd, H1 2019
Diabetic Peripheral Neuropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2019
Diabetic Peripheral Neuropathy - Pipeline by Neuralstem Inc, H1 2019
Diabetic Peripheral Neuropathy - Pipeline by Reata Pharmaceuticals Inc, H1 2019
Diabetic Peripheral Neuropathy - Pipeline by Relief Therapeutics Holding AG, H1 2019
Diabetic Peripheral Neuropathy - Pipeline by Sphaera Pharma Pte Ltd, H1 2019
Diabetic Peripheral Neuropathy - Pipeline by ViroMed Co Ltd, H1 2019
Diabetic Peripheral Neuropathy - Dormant Projects, H1 2019
Diabetic Peripheral Neuropathy - Discontinued Products, H1 2019

List of Figures
Number of Products under Development for Diabetic Peripheral Neuropathy, H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

【掲載企業】

Achelios Therapeutics Inc、Applied Therapeutics Inc、Celularity Inc、Commence Bio Inc、Grunenthal GmbH、Immune Pharmaceuticals Inc、Medifron DBT Co Ltd、Mitsubishi Tanabe Pharma Corp、Neuralstem Inc、Reata Pharmaceuticals Inc、Relief Therapeutics Holding AG、Sphaera Pharma Pte Ltd、ViroMed Co Ltd

★調査レポート[糖尿病性末梢神経障害治療薬の世界市場:パイプラインレビュー(2019上半期)] (コード:DATA906A140)販売に関する免責事項を必ずご確認ください。
★調査レポート[糖尿病性末梢神経障害治療薬の世界市場:パイプラインレビュー(2019上半期)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆